Industry News

- Read more about Eli Lilly expands its R&D facility in New York
Eli Lilly and Company plans to add 30,000 square feet and approximately 50 new jobs to its research and development presence at the Alexandria Center for Life Science in New York, New York.

[adsense:336x280:8701650588]
- Read more about US FDA approve Alkermes' injectable Aristada
The US Food and Drug Administration approved Alkermes Inc's Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Schizophrenia is a chronic, severe and disabling brain disorder affecting about one percent of Americans. Typically, symptoms are first seen in adults younger than 30 years of age. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.
- Read more about Cipla Medpro collaborate with Serum Institute to provide vaccines in South Africa
Cipla Medpro (Pty) Ltd., South African subsidiary of Cipla Ltd. has recently entered into an exclusive agreement with the world’s largest vaccine manufacturer, Serum Institute of India (SII) in South Africa. The partnership will not only enable affordable and accessible vaccines for South Africans, but will also facilitate a reliable supply stream to the South African Government.
- Read more about Sun Pharma settles patent litigation with Actavis Group
Sun Pharmaceutical Industries announced that Ranbaxy Pharmaceuticals Inc. (Ranbaxy), a wholly-owned subsidiary, along with its partners, Cipher Pharmaceuticals Inc. (Cipher) and Galephar Pharmaceutical Research, Inc. (Galephar) have entered into a settlement agreement with Actavis Group (Actavis) that dismisses the patent litigation suit relating to Actavis’ Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules). Absorica is the registered trademark of Ranbaxy Laboratories Inc.
- Read more about Impax Lab generic glyburide tablets approved by US FDA
Impax Laboratories, Inc., a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved its generic version of glyburide tablets 1.25 mg, 2.5 mg, and 5 mg. The company is preparing for commercialisation of this product through Impax's generic division.
- Read more about Nestle India asks why fresh tests on Maggi
Nestle India on asked the apex consumer court why fresh tests were being ordered on Maggi noodles on food safety when a similar exercise has already been conducted as per directions of the Bombay High Court.
- Read more about Allergan's Juvederm Ultra XC receive US FDA marketing nod
Allergan plc,, a leading global pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to market Juvederm Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21.
- Read more about HC hold back Glenmark from selling anti-diabetes drugs of MSD
The Delhi High Court on Wednesday restrained Mumbai-based Glenmark Pharmaceuticals Ltd from making or selling its generic anti-diabetes drugs Zita and Zita-Met while holding it infringing patent of a US drug maker Merck, Sharp and Dohme Corporation. (MSD)
- Read more about MSF calls for cautious approach on EU-India free trade agreement
International medical aid agency Medecins Sans Frontieres (MSF/Doctors Without Borders) on Wednesday called for a cautious approach from Indian negotiators on the reinstatement of talks for the EU-India free trade agreement which was discussed during German Chancellor Angela Merkel's visit.

[adsense:336x280:8701650588]
- Read more about Sandoz's BLA For Biosimilar Etanercept Accepted by USFDA
Sandoz, a Novartis company and the global leader in biosimilars, announced that US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen's US-licensed Enbrel (etanercept) - a tumour necrosis factor alpha (TNF-alpha) inhibitor. This is the second BLA submission by Sandoz using the 351(k) biosimilar pathway.